Adults with bipolar I disorder who switched to an aripiprazole injection given every 2 months had more days covered by medication over the next 6 months than in the 6 months before, according to a US insurance-claims study of 1,467 people.1 Hospital stays and medical costs fell too, but the study had no comparison group …
A 2026 German-Austrian cohort analysis found that people with schizophrenia who were taking quetiapine scored modestly higher on demanding working-memory tests than sex- and age-matched patients who were not, with the largest gap at doses of 300 mg a day or less.1 Because patients were not randomized to quetiapine, this is an association; the advantage …
A 2026 analysis of 41 randomized studies involving 21,025 adults with schizophrenia found the largest estimated reductions in hostility and aggression for clozapine (standardized mean difference, or SMD, of −0.75), paliperidone (−0.62), and olanzapine (−0.60) vs. placebo.1 Confidence in every comparison was low or very low, the top 3 were not statistically separable, and most …
A 2026 case report described valproate 800 mg/day improving agitation in residual-phase treatment-resistant schizophrenia but being followed by hypoglycemia and pancytopenia; after discontinuation, lithium 600 mg/day at 0.8 mEq/L was associated with BPRS improvement from 80 to 64.1 The calibrated read is mixed: valproate looked behaviorally useful in 1 patient, but the safety signal was …
A 2026 randomized study involving 80 people with schizophrenia found that adding high-frequency repetitive transcranial magnetic stimulation to risperidone improved PANSS cognitive-factor scores and aggressive-behavior ratings more than risperidone alone over 4 weeks.1 Research Highlights Design was randomized but short: 80 patients were assigned to risperidone alone or risperidone plus rTMS, 40 per group, with …
A 2026 cross-sectional schizophrenia study found no meaningful association between antipsychotic dose and Montreal Cognitive Assessment (MoCA) performance in young, clinically stable outpatients. Cognitive scores related more strongly to symptom burden, illness duration, education, and age at diagnosis than to daily or 1-year cumulative antipsychotic exposure.1 Research Highlights Daily dose was not linked to MoCA: …
A 2026 FAERS pharmacovigilance study of 28,938 dystonia reports found the strongest reporting signal for metoclopramide, while antipsychotics dominated the high-volume psychiatric medication signal and most timed cases began within 30 days of drug exposure.1 Research Highlights 28,938 dystonia reports: Chen et al. analyzed 27,618 patients represented in FAERS reports from Q1 2004 through Q3 …